Key stats
About Tidal Trust II Defiance Daily Target 2X Long LLY ETF
Expense ratio
1.29%
Home page
Inception date
Aug 7, 2024
LLYX uses swap agreements to make bullish bets on Eli Lilly and Companys (NYSE: LLY) share price. LLY is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines in various therapeutic areas, including neuroscience, endocrinology, oncology, cardiovascular diseases, and immunology. The fund maintains a daily leveraged exposure equivalent to 200% of the funds net assets through daily rebalancing. As a geared product, the fund is intended as a short-term tactical tool, rather than as a long-term investment vehicle. As a result, returns may deviate from the expected 2x if held for longer than a single day due to compounding. This strategy is high-risk and does not include a defensive position as part of its overall process. Additionally, the fund could potentially lose money over time, even if LLY's performance strengthens. The fund is expected to invest in cash-like instruments as collateral.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Cash
Stocks2.70%
Health Technology2.70%
Bonds, Cash & Other97.30%
Cash89.61%
Mutual fund7.69%
Stock breakdown by region
North America100.00%
Latin America0.00%
Europe0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history